Dijie Liu

Title: The Innovations of Dijie Liu

Introduction

Dijie Liu is an accomplished inventor based in Coralville, IA (US). He has made significant contributions to the field of biomedical research, particularly in the development of peptides targeting fibroblast activation protein alpha (FAP). His innovative work has the potential to impact therapeutic strategies in various medical applications.

Latest Patents

Dijie Liu holds a patent for "Fibroblast activation protein targeting peptides." This invention relates to a specific structure of peptides, denoted as A-[Z-AA-AA-AA-AA-AA-AA-AA-Z]-B. In this structure, A represents the N-terminal, B represents the C-terminal, and each Z and AA corresponds to residues of amino acids. The peptides can be either linear or cyclized, showcasing Liu's creativity in peptide design.

Career Highlights

Dijie Liu is currently associated with Perspective Therapeutics, Inc., where he continues to advance his research and development efforts. His work is pivotal in exploring new avenues for targeted therapies, particularly in oncology and other diseases where FAP plays a crucial role.

Collaborations

Dijie Liu collaborates with notable colleagues, including Michael K Schultz and Mengshi Li. These partnerships enhance the research environment and foster innovation within the team.

Conclusion

Dijie Liu's contributions to the field of peptide research exemplify the spirit of innovation. His patent on fibroblast activation protein targeting peptides represents a significant advancement in therapeutic development. Through his work at Perspective Therapeutics, Inc., Liu continues to push the boundaries of biomedical research.